Navigation Links
TPI Discusses Non-Cash Non-Operational Financial Impact from Warrants
Date:6/17/2011

CHENGDU, China, June 17, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, the "Company"), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today discussed the non-cash, non-operational financial impact from the warrants issued in January 2008 under the ASC 815-40-15 (formerly EITF 07-05).

In the financial report of Third quarter fiscal year 2011 ending March 31, 2011, the Company has disclosed that under ASC 815-40-15, the Company's accounting treatment of the Series A and B warrants from July 1, 2009 until December 31, 2010 is subject to revisions. Due to the presence of certain anti-dilutive (down round protection) clauses in both warrants during the above period, these financial instruments have been re-categorized as liabilities while they were previously treated as equity.

On January 14, 2011, these anti-dilutive clauses in both series of warrants were removed therefore the warrants were re-categorized as equity in the third quarter of fiscal year 2011 while the accounting issues related to the warrants ceased to exist.

Based on the warrants' exercise data and weighted valuation, the Company has calculated the non-cash impact for the fiscal year 2010 and the first two quarters of fiscal year 2011. The analysis indicated that

  1. The non-cash impact from the warrants for fiscal year 2010 ending June 30, 2010 was a loss of ($0.16) million, or (1.07%) to pretax net income of $14.7 million
  2. The non-cash impact from the warrants for the first two quarters of fiscal year 2011 was a gain of $1.28 million, or 12.9% to net income for the first two quarters of fiscal year 2011 of $9.9 million.

Management and the Board of Directors of the Company discussed this matter with the Company's principal accountants and de
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
2. VHGI Discusses Recent Addition to the Regulation SHO Threshold Security Listing
3. Robotic Surgery Expert Dr. David B. Samadi, MD Discusses New Evidence That Proves The Low Complication Rates of Robotic Prostatectomy
4. With Over 3,000 Robotic Prostatectomy Surgeries to His Credit, Dr. David Samadi, MD Discusses SMART Surgery and How it Improves Sexual and Urinary Function
5. Prostate Cancer Treatment Expert Dr. David Samadi, MD Discusses Study Which Found That Low-Income Men Had High-Risk Prostate Cancer Tumors
6. Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Treatment Drug Abiraterone
7. Robotic Surgery Expert Dr. David Samadi, MD Discusses FDA Warnings on the Effect of GnRH Agonists
8. New York Robotic Surgery Expert Dr. David Samadi, MD Discusses New Findings that Hormone Therapy May Increase Risk of Developing Colorectal Cancer
9. Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Staging and Prostate Cancer Recurrence Study
10. Dr. David B. Samadi Discusses Why Robotic Surgery is Quickly Becoming the Go-To Standard for Prostate Cancer Treatment
11. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Sep. 03, 2015 Research ... of the "Investigation Report on China,s Raloxifene Market, ... to the statistics, over 200 million people suffer from ... above in China , 50% have ... 30%-50% among women aged 60 and above. Raloxifene ...
(Date:9/3/2015)... -- China,s startup business ExtantFuture ... wearable medical device that can continuously monitor the fetal ... guidance for pregnant women. The device will debut on ... measures 4 centimeters in diameter, is as thin as ... an Apple earphone cord. The small and compact device ...
(Date:9/3/2015)... Sept. 3, 2015 HeartWare International, Inc ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... its President and Chief Executive Officer, Doug Godshall ... Fargo Healthcare Conference at 8:50 a.m. ET on Wednesday, ... 2015 at The Hyatt Regency, Boston ...
Breaking Medicine Technology:Investigation Report on China's Raloxifene Market, 2015-2019 2Modoo to Debut at Kickstarter: First Device on the Market that Enables Continuous Monitoring of Fetal Heart Rate and Fetal Movement 2HeartWare Presentation At The 2015 Wells Fargo Healthcare Conference To Be Webcast 2
... 28 Parents may be giving their children ... research being presented this week at Research Forum ... American College of Emergency Physicians.  Two studies are ... Medication Dosing Cups Are Inaccurate" and "Do Parents ...
... YORK, Sept. 27 Pfizer Inc. announced today ... trial evaluating SUTENT® (sunitinib malate) in combination with ... (CRPC) that had progressed despite treatment with a ... an independent Data Monitoring Committee (DMC) found that ...
Cached Medicine Technology:Warnings Re: Over-the-Counter Medication for Children: Less is More 2Pfizer Discontinues Phase 3 Trial of SUTENT® in Advanced Castration-Resistant Prostate Cancer 2Pfizer Discontinues Phase 3 Trial of SUTENT® in Advanced Castration-Resistant Prostate Cancer 3Pfizer Discontinues Phase 3 Trial of SUTENT® in Advanced Castration-Resistant Prostate Cancer 4
(Date:9/3/2015)... VA (PRWEB) , ... September 03, 2015 , ... ... the Spouse/Caregiver Scholarship applications are open for spring 2016. Scholarships are awarded two ... members. Hope For The Warriors® is a national nonprofit dedicated to restoring a ...
(Date:9/3/2015)... ... September 03, 2015 , ... Advice columnist, professional ... her debut book, “Stop Wasting Your Time Blaming Others for Your Life.” , ... guide to overcoming life’s obstacles by taking full responsibility for one’s life shares ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... comprehensive eating disorder treatment for adults and adolescents struggling with anorexia, bulimia, ... has joined the medical treatment team. As a Staff Psychiatrist, Dr. Calinoiu ...
(Date:9/3/2015)... ... 2015 , ... As a result of the Patient Protection ... insurance plans, more employers are moving to a self-funded model for pharmacy plans, ... United Benefit Advisors (UBA) Health Plan Survey. , UBA’s survey, the nation’s largest ...
(Date:9/3/2015)... ... 03, 2015 , ... ProScrub is a set of automated tools that allow ... custom speed effects without the use of keyframes. Utilize ProScrub's powerful sliders to ... are perfect complements to energetic video productions. ProScrub is a Final Cut ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2
... , , SAN RAMON, Calif., ... who plays Dwight Schrute on NBC,s hit show The Office, ... night, August 15, at the home of Gouya and Payam Zamani, ... Mona Foundation, a non-profit organization that supports social and economic development ...
... juice to combat urinary tract infections is ,unsatisfactory and ... day..." Not all medical problems require a state-of-the-art solution, ... from the corner shop could treat a widespread and ... touted as a simple solution for urinary tract infections, ...
... , , , ... a leading national law firm in the fight against mesothelioma and ... foremost trial attorneys in the country, has joined the firm as ... of asbestos cancer cases since the late 1970s. He has successfully ...
... , , , ... sanofi-aventis U.S. announced today that the U.S. Food and Drug ... six months and older for the relief of symptoms of ... hives) and for children age two years and older for ...
... Avacor ( ) P r oducts LLC ... in the hair re-growth industry, has recently teamed up with two charitable organizations, ... ), and Team Continuum ( http://www.teamcontinuum.net ). ... fighting cancer as well as to help find new ways to fight this prolific ...
... , ST. LOUIS, Aug. 24 ... the herbicide Atrazine have attorney and clean water advocate Steve ... transparency and accountability for the herbicide,s manufacturers. , , ... in the New York Times and the Peoria Journal Star ...
Cached Medicine News:Health News:Rainn Wilson ('Dwight' on The Office) Joins Reply.com at Fundraiser for Mona Foundation 2Health News:Decorated Trial Attorney Conard Metcalf Joins Simmons Firm as 'Of Counsel' 2Health News:Decorated Trial Attorney Conard Metcalf Joins Simmons Firm as 'Of Counsel' 3Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 2Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 3Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 4Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 5Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 6Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 7Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 8Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 9Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 10Health News:Avacor(R), a Leader in Hair Regrowth, Announces Charities of Choice: Team Continuum and City of Hope 2Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 2Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 3
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Severe revision options for the knee and hip...
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Medicine Products: